BMO Capital analyst Etzer Darout lowered the firm’s price target on Arvinas (ARVN) to $88 from $90 but keeps an Outperform rating on the shares. The company expects to disclose pivotal data evaluating vepdegestrant in ER+/HER2- breast cancer patients in Q1 of 2025, and the firm is maintaining its positive view on Arvinas’ protein degrader platform and ARV-471 in ER+/HER2- breast cancer, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN: